Literature DB >> 20584879

Rosiglitazone and the case for safety over certainty.

David N Juurlink.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20584879     DOI： 10.1001/jama.2010.954

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  Uptake of novel medical therapies in the general population.

Authors:  C M Booth; B Rapoport
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

2.  Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.

Authors:  Robert Ratner; Jenny Han; Dawn Nicewarner; Irina Yushmanova; Byron J Hoogwerf; Larry Shen
Journal:  Cardiovasc Diabetol       Date:  2011-03-16       Impact factor: 9.951

3.  Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery.

Authors:  Radda Rusinova; Karl F Herold; R Lea Sanford; Denise V Greathouse; Hugh C Hemmings; Olaf S Andersen
Journal:  J Gen Physiol       Date:  2011-08       Impact factor: 4.086

Review 4.  The forgotten type 2 diabetes mellitus medicine: rosiglitazone.

Authors:  Bo Xu; Aoxiang Xing; Shuwei Li
Journal:  Diabetol Int       Date:  2021-06-29

Review 5.  Thiazolidinediones: the Forgotten Diabetes Medications.

Authors:  Harold E Lebovitz
Journal:  Curr Diab Rep       Date:  2019-11-27       Impact factor: 4.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.